What have we learned from the recent trials looking at the ability of NGS to drive precision-based treatments across a broad spectrum of tumor subtypes? (Korean)

What have we learned from the recent trials looking at the ability of NGS to drive precision-based treatments across a broad spectrum of tumor subtypes? (Korean)

What have we learned from the recent trials looking at the ability of NGS to drive precision-based treatments across a broad spectrum of tumor subtypes?


Created by

CMEducation Resources IQ&A Interactive Intelligence Zone

Presenter

Professsor Hyun Cheol Chung, MD

Professsor Hyun Cheol Chung, MD

Professor of Medical Oncology
Director, Yonsei Song-Dang Institute for Cancer Research
Yonsei University College of Medicine
Seoul, Korea